Abstract: Fibroblast growth factors (FGFs), a class of growth factors extensively found in organisms, are closely related to cell growth, proliferation and differentiation, and regulate various physiological and pathological processes by paracrine or endocrine effects. FGFs were initially found to play important roles in embryonic development and angiogenesis. With increasingly intensive and extensive studies on the FGF family members, it has been recently found that the endocrine growth factors FGF19, FGF21 and FGF23 and the paracrine growth factor FGF1 in this family play important roles in regulating metabolic diseases caused by glycolipid metabolic disorders, providing new approaches for the diagnosis and treatment of various metabolic diseases. This paper focuses on the latest advances and clinical applications of FGF family members in metabolic diseases.